NICE guidance - orlistat for the treatment of obesity
Last reviewed 05/2021
Summary points of the guidance on the use of orlistat for the treatment of obesity in adults:
- orlistat should be prescribed only as part
of an overall plan for managing obesity in adults who meet one of the following
criteria:
- a BMI of 28.0 kg/m2 or more with associated risk factors
- a BMI of 30.0 kg/m2 or more
- therapy should be continued beyond 3 months only if the person has lost at least 5% of their initial body weight since starting drug treatment
- the decision to use drug treatment for longer than 12 months (usually for weight maintenance) should be made after discussing potential benefits and limitations with the patient
- the coprescribing of orlistat with other drugs aimed at weight reduction is not recommended
Notes:
- rates of weight loss may be slower in people with type 2 diabetes, so less strict goals than those for people without diabetes may be appropriate. These goals should be agreed with the person and reviewed regularly
Reference: